1. Chen X, Song X, Li K, et al. FcγR-binding is an important functional attribute for immune checkpoint antibodies in cancer immunotherapy. Front Immunol. 2019;10:292.
2. Zhang T, Song X, Xu L, et al. The binding of an anti-PD-1 antibody to FcgammaRIota has a profound impact on its biological functions. Cancer Immunol Immunother. 2018;67(7):1079–90.
3. BeiGene. China National Medical Products Administration approves BeiGene’s tislelizumab for patients with classical Hodgkin’s lymphoma who have received at least two prior therapies. [media release] 27 Dec 2019. http://www.beigene.com.
4. BeiGene. Tislelizumab; China prescribing information [Chinese]. 2019. http://drugs.medlive.cn/drugref/html/21697.shtml. Accessed 10 Mar 2020.
5. BeiGene. BeiGene announces closing of global strategic oncology collaboration with Celgene Corporation. [media release] 31 Aug 2017. http://www.beigene.com.